http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1b1c3d60721dbbb749cdece6ec3c29b
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Miller |
| name | Wilson H Miller Wilson H. Miller |
| given-name | Wilson H. Wilson H |
| organization-name | From the Lady Davis Institute for Medical Research and SMBD Jewish General Hospital, McGill University, Montreal, QC, Canada; and Applied Genomics Inc, Sunnyvale, CA. Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada;; Rossy Cancer Network, McGill University, Montreal, QC H3H 1E8, Canada; 1Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. From the University of Miami and Sylvester Cancer Center, Miami, FL; Medical University of South Carolina, Charleston, SC; US Oncology, Dallas, TX; Pfizer Corporation, New York, NY; Jewish General Hospital, Montreal, Quebec, Canada; Christchurch Hospital, Christchurch, New Zealand; and Pharmacia Italy SPA, Pfizer Group, Nerviano, Italy 9Department of Medicine, Segal Cancer Center and Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman,... for the COVID-19 and Cancer Consortium Segal Cancer Center Lady Davis Institute for Medical Research SMBD Jewish General Hospital McGill University Montreal Quebec Canada 1Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; 2Department of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; 9Rossy Cancer Network, McGill University, Montréal, Québec, Canada. Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montréal, QC H3T 1E2, Canada Authors' Affiliations: 1Lady Davis Institute for Medical Research, Segal Cancer Center, Jewish General Hospital, McGill University, Montréal, Quebec, Canada; and 2Division of Hematology/Oncology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois From the Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, and the McGill University Department of Oncology and Medicine, Montreal, Quebec, Canada; Montefiore Medical Center and Albert Einstein Cancer Center, Bronx, NY; and Dipartimento di Istologia ed Embriologia Medica, Universitàdi Roma “La Sapienza,” Rome, Italy. From the Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University Department of Oncology and Medicine, Montreal, Quebec, Canada; Dipartimento di Istologia ed Embriologia Medica, Università di Roma “La Sapienza,” Rome, Italy; and Department of Medicine/Neoplastic Diseases, New York Medical College, Valhalla, NY. From the Lady Davis Institute for Medical Research, the Department of Pathology, Sir Mortimer B. Davis Jewish General Hospital and McGill University Departments of Experimental Medicine, Oncology, and Medicine, Montreal, Quebec, Canada; and Ligand Pharmaceuticals Inc, San Diego, CA. From Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Clinical and Translational Research, Winship Cancer Institute at Emory University, Atlanta, GA; Ligand, San Diego, CA; US Oncology, Rocky Mountain Cancer Centers, Houston, TX; Zentralkrankenhaus Gauting, Abteilung Onkologie, Gauting bei Muenchen; Grosshansdorf Hospital, Grosshansdorf; Zentralkrankenhaus, Gauting, Germany; Department of Oncology, Sir Mortimer B. Davis - Jewish... James Larkin, Royal Marsden NHS Foundation Trust, London; Paul Lorigan, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; David Minor, California Pacific Medical Center Research Institute; Adil Daud, University of California San Francisco, San Francisco; Bartosz Chmielowski, University of California, Santa Monica, CA; Sandra D'Angelo, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Jeffrey Weber, Perlmutter Cancer Center at New York... Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC; Jewish General Hospital, Montréal, QC; Authors' Affiliations: Sir Mortimer B. Davis Jewish General Hospital Segal Cancer Center, and Department of Oncology, McGill University, Montreal, Quebec, Canada Department of Medicine, Lady Davis Institute for Medical Research and Segal Cancer Center, SMBD Jewish General Hospital, Faculty of Medicine, McGill University, Montreal, Canada; Department of Oncology, Lady Davis Institute for Medical Research and Segal Cancer Center, SMBD Jewish General Hospital, Faculty of Medicine, McGill University, Montreal, Canada From the Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Vanderbilt University Medical Center, Nashville, TN; Tom Baker Cancer Centre, Calgary, Alberta, Canada; Wojewódzki Szpital, Krakow, Poland; McGill University-Jewish General Hospital, Montreal, Quebec, Canada; St László Hospital, Budapest, Hungary; Sanofi-aventis, Bridgewater, NJ; and the Instituto Nacional do Câncer, Rio de Janeiro, Brazil From the Department of Medicine, Division of Medical Oncology, Mount Sinai School of Medicine, New York, NY; the Shanghai Institute of Hematology, Shanghai Second Medical University, Shanghai, China; and Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada. From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital–Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) — all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) —... Department of Oncology, McGill University Lady Davis Institute for Medical Research and Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal H3T 1E2, Quebec, Canada. 1Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.; 2Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.; 17Montreal Rossy Cancer Network, Montréal, Québec, Canada. 1Segal Cancer Center and Lady Davis Institute of the Jewish General Hospital for Medical Research and; 2Department of Oncology, McGill University, Montreal, Quebec, Canada; 1Lady Davis Institute for Medical Research, McGill University, Quebec, Canada.; 11Department of Oncology, McGill University, Quebec, Canada. Departments of Oncology and Medicine, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, Quebec, Canada Authors' Affiliations: 1University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado; 2Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, Scottsdale, Arizona; 3Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; 4Yale Cancer Center, New Haven, Connecticut; 5Tom Baker Cancer Center, Calgary, Alberta, Canada; 6Stanford University, Redwood City, California; 7Infinity Pharmaceuticals, Cambridge, Massachusetts; and 8Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland Lady Davis Institute, McGill University, Montréal, Canada; Department of Experimental Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada 1Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; 2Lady Davis Institute for Medical Research, McGill University, Montréal, Québec, Canada.; 5Department of Medicine, McGill University, Montréal, Québec, Canada.; 6Department of Medicine, Jewish General Hospital, Montréal, Québec, Canada.; 7Department of Oncology, Jewish General Hospital, Montréal, Québec, Canada.; 8Department of Oncology, McGill University, Montréal, Québec, Canada. John P. Crown, Irish Cooperative Oncology Research Group, Dublin, Ireland; Véronique Diéras, Institut Curie, Paris; Thomas Bachelot, Centre Léon Bérard, Lyon; Olivier Capitain, Centre Paul Papin, Angers; Gilles Romieu, Regional Centre for the Fight Against Cancer Val d'Aurelle Paul-Lamarque, Montpellier, France; Elzbieta Staroslawska, Centrum Onkologii Ziemi Lubelskiej, Lublin; Maria Blasinska-Morawiec, Wojewodzki Szpital Specjalistyczny, im M. Kopernika, Lodz, Poland; Denise A. Yardley, Sarah Cannon... Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University Departments of Oncology and Medicine, Montréal, Québec, Canada From the Department of Medicine, Division of Experimental Medicine, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and the Cell Biology Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, NY. From the Lady Davis Institute for Medical Research and Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada. 1Departments of Oncology and Experimental Medicine, McGill University, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. From the Department of Medicine, Massachusetts General Hospital, Boston, MA; Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine; St Petersburg City Oncology Center, St Petersburg, Russian Federation; Kansas City Cancer Center, Kansas City, MO; McGill University, Montreal, Quebec, Canada; and Intarcia Pharmaceutics Inc, Emeryville, CA From the Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University Departments of Oncology and Medicine, Montreal, Quebec, Canada; the Dipartimento di Istologia ed Embriologia Medica, Università di Roma “La Sapienza”, Rome, Italy; and Ligand Pharmaceuticals Inc, San Diego, CA. Sandra P. D’Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University... From the Unité de Recombinaison et Expression Génétique, INSERM U 163, Institut Pasteur, Paris, France; and the Lady Davis Institute for Medical Research, McGill University, Montreal, Canada. From the Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Weill Medical College of Cornell University, New York, NY, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada. Lady Davis Institute for Medical Research, Segal Cancer Center, McGill University, Montreal, Quebec, Canada 1Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital, Department of Oncology, McGill University, Montreal, Quebec, Canada; Department of Oncology McGill University Montreal Quebec Canada Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada; Departments of Oncology and Medicine, McGill University, Montreal, QC, Canada 11Jewish General Hospital and Segal Cancer Centre, McGill University, Montréal, Canada. From the Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada; McGill University Departments of Oncology and Medicine, Montreal, Canada; Department of Histology and Medical Embryology, University “La Sapienza,” Rome, Italy; Department of Clinical and Experimental Medicine, General Pathology Section, Perugia University, Italy; and San Raffaele Bio-medical Science Park, Rome, Italy. Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Québec, Canada Lawson Health Research Institute CIHR Strategic Training Program in Cancer Research and Technology Transfer and Western University, London, ON N6A 4L6, Canada Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital Segal Cancer Center, and McGill University Department of Oncology, Montreal, Quebec, Canada From the Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada, and Mount Sinai School of Medicine, New York, NY. 5Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada; Jewish General Hospital, Segal Cancer Centre, Department of Oncology, Montreal, QC, Canada; Rossy Cancer Network, Montreal, QC, Canada. Electronic address: wmiller@ldi.jgh.mcgill.ca. From the Lady Davis Institute for Medical Research, McGill University, Montreal, QC; and the Department of Chemistry, McGill University, Montreal, QC. |
Incoming Links
Total number of triples: 236.